

**CURRICULUM VITAE****EUGENE H. MAKELA**

Office School of Pharmacy  
 Address PO Box 9520  
 West Virginia University  
 Morgantown, West Virginia 26506-9520  
 Office Phone (304) 293-1456  
 Page Access (304) 598-4789, pager 0919  
 Fax (304) 293-7672  
 Internet gmakela@hsc.wvu.edu

Home 670 Colonial Drive  
 Address Morgantown, West Virginia 26505  
 Home Phone (304) 599-6264

Birthdate February 27, 1951

**EDUCATION**

1984-1986	Medical University of South Carolina	Doctor of Pharmacy
1973-1976	University of Florida	Bachelor of Science, Pharmacy
1969-1976	University of Florida	Bachelor of Science, Mathematics

**APPOINTMENTS AND POSITIONS****ACADEMIC**

1995-Present Associate Professor, Department of Clinical Pharmacy, School of Pharmacy, and Associate Professor, Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV.

1989-1995 Assistant Professor, Department of Clinical Pharmacy, School of Pharmacy, and Associate Professor, Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV.

1986-1989 Adjunct Assistant Professor, School of Pharmacy, University of Maryland at Baltimore, Baltimore, Maryland, 1986-1989.

**NON-ACADEMIC**

1986-1989 Director of Clinical Pharmacy Services, Thomas B. Finan Center, State of Maryland Department of Health and Mental Hygiene, Cumberland, Maryland.

1982-1984 Director of Pharmacy, Blue Ridge Hospital Division, University of Virginia Hospitals, Charlottesville, Virginia.

1980-1982 Staff Pharmacist, Blue Ridge Hospital, Division of the University of Virginia, Charlottesville, Virginia.

- 1978-1980 Staff Pharmacist, University of Virginia Medical Center, Charlottesville, Virginia.  
 1976-1977 Staff Pharmacist, North Florida Regional Hospital, Gainesville, Florida.  
 1976 Community Pharmacist, Revco Pharmacy, Lake City, Florida.

### **PHARMACY LICENSURE AND CERTIFICATION**

- 1989-Present Registered Pharmacist (#4942) State of West Virginia  
 1976-Present Registered Pharmacist (#8049) State of Alabama  
 1976-Present Registered Pharmacist (#15455) State of Florida  
 1996-Present Board Certification, Psychiatric Pharmacy

### **HONORS AND AWARDS**

- 2006 Recognized by the National Alliance for the Mentally Ill (NAMI) for exemplary work in facilitating efforts by which the College of Psychiatric and Neurologic Pharmacists can work with NAMI to better meet the needs of those with mental illness.  
 2003 Named *Teacher of the Year* by the 3rd Professional Year Pharmacy Class.  
 1996 Awarded tenure at West Virginia University School of Pharmacy.  
 1994 *New Investigator Award*, 34th Annual Meeting of the New Clinical Drug Evaluation Unit, Division of Clinical and Treatment Research, National Institute of Mental Health, Marco Island, Florida, June, 1994; title of research: "Obsessive-Compulsive Symptoms and Standardized Reading Test Scores."  
 1990 Elected to membership in *Phi Lambda Sigma, National Pharmacy Leadership Society*.  
 1986 Elected to membership in *Rho Chi Pharmaceutical Honor Society*.  
 1969 Recipient, *Dale H. Boggy Award for Meritorious Service*, North Miami Senior High School, North Miami, Florida, 1969.  
 1968 *Honorable Mention*, Ford Future Scientists of America competition and *Finalist*, *Westinghouse Talent Search* for project "Base Ratio of Mutant DNA."

### **MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

- 2001-2006 American College of Clinical Pharmacy  
 1995-Present College of Psychiatric and Neurologic Pharmacists  
 1991-Present American Association of Colleges of Pharmacy  
 1977-Present American Society of Health-System Pharmacists

### **TEACHING RESPONSIBILITIES**

**WEST VIRGINIA UNIVERSITY, 1989 to Present**

#### **SCHOOL OF PHARMACY**

Residency Training Director, Psychiatric Pharmacy

2007-2008	Chrisopher Paxos
2005-2006	Karen Baird, Pharm.D.
2004-2005	Lisa Giblin, Pharm.D.
2003-2004	Missy Latocha, Pharm.D.
2002-2003	John Pope, Pharm,D,
2001-2002	Karen Moeller, Pharm.D., BCPP
2000-2001	Jennifer Fullen, Pharm.D., BCPP

#### Graduate Committee Member

Current	Andrea Pfalzgraf, Anuja Roy
2005	Mariam Hassan, Ph.D.
2004	Iftekhar Kalsekar, Ph.D.
2003	Lee Ann Thayer, M.S.

#### Major Project Supervisor, Post-Baccalaureate Doctor of Pharmacy Program

1995-1996	Denise Fletcher, Pharm.D.
1995-1996	Patricia McCormick, Pharm.D.

#### Doctor of Pharmacy Courses

2002-Present	Pathophysiology and Therapeutics IV (Course and Section Coordinator)
2002-Present	Pharmacy as a Profession (Guest Lecturer)
2002-Present	Therapeutic Patient Monitoring (Guest Lecturer)
2000-2005	Non-Prescription Drugs (Guest lecturer)
2000-Present	Pharmaceutical Care Laboratory (Instructor)
2002-Present	Patient Health Education
1997-Present	Experiential Rotation in Psychiatry (Primary Instructor)
1994-2001	Disease Processes and Therapeutics (Course and Module Coordinator)
1994-2000	Advanced Clinical Pharmacokinetics (Guest Lecturer)

#### Baccalaureate in Pharmacy Courses

1989-2000	Medical Teams Clerkship (Primary Instructor)
1990-1998	Pharmacotherapeutics (Guest Lecturer)
1991-6, 1998	Pharmaceutical Investigations (Course Coordinator)
1994-1998	Chemical Abuse (Course Coordinator)
1997-9	Principle of Pharmacy Practice (Guest Lecturer)
1990-1996	Principles of Medicine (Guest lecturer)
1991-3, 1996	Special Topics in Clinical Pharmacy (Primary Instructor)
1990	Geriatric Pharmacy (Guest Lecturer)

#### **SCHOOL OF MEDICINE**

Department of Behavioral Medicine and Psychiatry

2006 Introduction to Psychopharmacology for Medical Students  
 1993-Present Psychiatry Lecture Series for medical students (Lecturer)  
 1998-Present Outcome Studies in Psychiatry for psychology interns (Lecturer)  
 1990-2005 Thought Disorders Lecture Series for residents (Guest Lecturer)  
 2002, 2005 Advanced Psychopharmacology for residents  
 2001- 2005 Clinical Psychopharmacology for residents (Course Coordinator, lecturer)  
 2001 Substance Disorder Seminar for residents (Lecturer)  
 1995-2000 Clinical Psychopharmacology for residents (Lecturer)  
 1998-2000 Psychobiology of Psychiatric Disorders for residents (Course Coordinator)  
 2000 Research Methods in Psychiatry (Guest Lecturer)  
 1992-1994 Anxiety Disorders Lecture Series for residents (Lecturer)  
 1992 Neuropsychiatry Lecture Series for residents (Lecturer)

Department of Occupational Therapy

2000 Medications in Psychiatry, Department of Human Performance and Applied Exercise Science (Guest Lecturer)

**SCHOOL OF NURSING**

2000 Pharmacology for the Advanced Practical Nurse (Lecturer)

**COLLEGE OF ARTS AND SCIENCES**

1998, 2000 Biological Bases of Behavior, Department of Psychology (Lecturer)  
 2002,  
 2004-Present

**UNIVERSITY OF MARYLAND COLLEGE OF PHARMACY**

1986-1989 Therapeutics (Lecturer)  
 1986-1989 Experiential Clerkship in Psychiatry (Primary Instructor)

**OTHER TEACHING EXPERIENCES**Allegany Community College, Cumberland, MD

1987 Pharmacology for Nurses (Course Coordinator, Primary Instructor)

Piedmont Virginia Community College, Charlottesville, VA

1978-1980 Pharmaceutical Science for Pharmacy Technicians (Course Coordinator, Primary Instructor)

1978-1980      Pharmacology for Nurses (Course Coordinator, Primary Instructor)

**SERVICE****Professional Organizations**College of Psychiatric and Neurologic Pharmacists

2005-Present	National Alliance for the Mentally Ill Relationship Management Group - fostered development of NAMI website offerings: medication fact sheets - initiated, directed website column "ask the psychiatric pharmacist" - facilitated development of university NAMI groups nationwide
2003-2005	Board of Advisors
2002-2005	Public and Professional Relations Committee
2001-2003	Board of Directors (elected position)
2001-2003	Awards and Nominations Committee
2001	Mentoring Task Force
2000-2001	Vice-Chair, Committee on Board Recertification
1994-5	Outreach Committee

American Pharmaceutical Association

1999	Chair, Specialty Council on Psychiatric Pharmacy Practice, Board of Pharmaceutical Specialties
1998	Vice-Chair, Specialty Council on Psychiatric Pharmacy Practice, Board of Pharmaceutical Specialties
1997-1999	Member, Specialty Council on Psychiatric Pharmacy Practice, Board of Pharmaceutical Specialties

American Society of Health-System Pharmacists

1993-1994	Co-Chairperson, Contemporary Issues Committee, Psychopharmacy Specialty Practice Group
1991-1993	Research Committee, Psychopharmacy Specialty Practice Group
1992	Member, Education and Programming Committee, Psychopharmacy Specialty Practice Group, American Society of Hospital Pharmacists

**West Virginia University**University

2004-present	Faculty sponsor, National Alliance for the Mentally Ill, West Virginia University (NAMI-WVU)
1993-1994	Health Sciences Center representative, Alcohol and Other Drugs Advisory Council Student Education Committee
1992-Present	Health Sciences Center Psychopharmacology Consultant, Medical Access and Referral System (MARS)

School of Pharmacy

2000-Present Training Director, Residency in Psychiatric Pharmacy Practice  
 1992-Present Faculty Advisor, West Virginia University chapter, Phi Lambda Sigma,  
 Profession of Pharmacy Leadership Society  
 2000-2006 Library liaison  
 2003-Present Experiential Education Committee  
 2001-2004 Search Committee for Chair, Department of Clinical Pharmacy  
 1999, 2003- Chair, Search Committee for Pharmacokinetics faculty member  
 2004  
 1992-1997 Curriculum Committee  
 2001-2002  
 1999-2000 Non-Traditional Doctor of Pharmacy Program Academic Affairs Committee  
 2000 Non-Traditional Doctor of Pharmacy academic Affairs Committee  
 1998-1999 Residency/Fellowship Development Committee  
 1998 Non-Traditional Doctor of Pharmacy Admissions Committee  
 1997 Chair, School-wide Faculty Evaluation Committee  
 1996-1997 Accreditation Self-study Committee on Curriculum and Degrees  
 1995-1997 Co-Chair and Experiential Coordinator, School of Pharmacy Curriculum Design  
 Committee  
 1995 Strategic Planning Committees on Work Environment and Professional Degree  
 Development  
 1995 Strategic Planning Committee, Subcommittee on Work Environment  
 1995 Strategic Planning Committee, Subcommittee on Professional degree  
 Development  
 1993-1994 Elected Delegate, American Association of Colleges of Pharmacy  
 1993-1994 Faculty Secretary  
 1991-1994 School of Pharmacy Discipline Coordinator, University Affiliated Center for the  
 Developmentally Disabled  
 1990-3 Doctor of Pharmacy Program Planning Committee  
 1991, 1992 Recruitment Committee  
 1991 Self-study Committee on Student Affairs  
 1990 Awards Committee

Department of Clinical Pharmacy, School of Pharmacy

2003-2005 Department of Clinical Pharmacy Management Team  
 2001-2002 Search Committee, Cardiology Faculty Member  
 1999, 2002 Chair, Department Evaluation Committee  
 1990, 1992 Member, Department Faculty Evaluation Committee  
 1996, 2000  
 2005  
 1997 Doctor of Pharmacy Admissions Committee  
 1996, 1997 Clerkship Subcommittee

Department of Behavioral Medicine and Psychiatry, School of Medicine

2002-2005 Planning Committee Residents Research Retreat  
 2002-2006 Research Coordinator, Thought Disorders Program  
 2002-2006 Program Committee, Thought Disorders Seminar  
 2002-2005 Education Committee  
 2002-2006 Residency Training Committee  
 2003-2006 Coordinator, Residents Research Subcommittee  
 1998-Present Representative, West Virginia University Hospitals Pharmacy and Therapeutics Committee  
 2000-2005 Program Director, Annual West Virginia University Thought Disorders (Psychosis) Conference  
 1997-2006 Discipline Coordinator, Psychiatric Pharmacy Practice, William R. Sharpe, Jr. Psychiatric Hospital  
 1991-2006 Thought Disorders Study Group  
 1998, 2002 Program Director and presenter, Preceptorship in Psychiatry for representatives from GlaxoWellcome  
 1998-2001 Faculty Development Committee  
 1998-Present Planning Committee, Annual West Virginia University Psychosis Conference  
 1992, 1993 Research Committee  
 1991, 1992 Faculty Teaching Committee

### Reviewer

1989-Present Annals of Pharmacotherapy  
 1993-Present American Journal of Pharmaceutical Education  
 1995-1998 American Pharmacy  
 1995-2000 Journal of Clinical Psychopharmacology

### Other Service

2000 Expert Consensus Panel: Survey on Guidelines for Antipsychotic Medication Utilization Evaluation Criteria, The Expert Consensus Consortium.  
 1996 Faculty Scholarship Committee, Council of Faculties, American Association of Colleges of Pharmacy  
 1995-1996 Antidepressant Subcommittee, Medicaid / PEIA Drug Formulary Committee, State of West Virginia Department of Health and Human Resources  
 1995-1996 Antidepressant Subcommittee, Medicaid / PEIA Drug Formulary Committee, State of West Virginia Department of Health and Human Resources  
 1991-1993 Chairperson, Pharmacist Recovery Program Committee, West Virginia Pharmacists Association  
 1991-1993 Consultant for Compeer Program, Inc., The Mental Health Association of Monongalia County, Morgantown, West Virginia  
 1988-1989 Secretary of the Medical Staff, Thomas B. Finan Center (Maryland psychiatric Hospital), Cumberland, Maryland  
 1986-1989 Chairman, Pharmacy and Therapeutics Committee, Thomas B. Finan Center, (Maryland psychiatric hospital), Cumberland, Maryland

- 1986-1989 Member, Medical Staff, Thomas B. Finan Center (Maryland psychiatric hospital), Cumberland, Maryland
- 1987-1989 Member, Interdisciplinary Health Education Council, University of Maryland, Cumberland Area Health Education Center, Cumberland, Maryland
- 1986-1989 Member, Pharmacy Caucus, University of Maryland, Cumberland Area Health Education Center, Cumberland, Maryland
- 1986-1989 Member, State of Maryland Pharmacy and Therapeutics Committee, Maryland Department of Health and Mental Hygiene, Baltimore, Maryland
- 1986-1989 Member, Operations Committee, University of Maryland/State of Maryland Department of Health and Mental Hygiene psychiatric hospitals, Baltimore, Maryland
- 1984 Chairman, Pharmacy and Therapeutics Committee, Blue Ridge Hospital, Division of University of Virginia Hospitals, Charlottesville, Virginia
- 1984 Member, Quality Assurance Committee, Blue Ridge Hospital, Division of University of Virginia Hospitals, Charlottesville, Virginia
- 1981-1984 Member, Contingency Planning Committee, Blue Ridge Hospital, Division of University of Virginia Hospitals, Charlottesville, Virginia
- 1982-1984 Member, Pharmacy and Therapeutics Committee, University of Virginia Medical Center, Charlottesville, Virginia
- 1983 Chairman, United Way Fund Drive Campaign, Blue Ridge Hospital, Division of University of Virginia Hospitals, Charlottesville, Virginia
- 1975-1976 Member, Alcoholism Task Force (BACCHUS, Boost Alcohol Consciousness Concerning the Health of University Students), University of Florida, Gainesville, Florida
- 1972-1975 President, Treasurer, and Board Member of the Nellie Swanson Fulk Memorial Collegiate Living Organization, Gainesville, Florida
- 1974-1976 Class Representative, College of Pharmacy Student Council, University of Florida, Gainesville, Florida

### **SELECTED PRESENTATIONS**

1. Pharmacology of Bromocriptine, monthly conference of pharmacists and physicians, University of Virginia Medical Center, Charlottesville, VA, October, 1979.
2. Drug-Resistant Pulmonary Tuberculosis, Pharmacy Grand Rounds, Medical University of South Carolina, Charleston, SC, August, 1985.
3. Alzheimer's Disease: Pathophysiology and Drug Treatment," Pharmacy Grand Rounds, Medical University of South Carolina, Charleston, SC, October, 1985.
4. A Controversial Issue in Health Care: Prescribing by Pharmacists, Pharmacy Grand Rounds, Medical University of South Carolina, Charleston, SC, February, 1986.
5. Appropriate Use of Serum Digoxin Concentrations," presented to faculty as requirement for completion of the Doctor of Pharmacy degree, Medical University of South Carolina, Charleston, SC, May, 1986.
6. The Pharm. D. Degree and Communication Problems in Health Care, Nursing 86 International Journeys Medical/Surgical seminar, Tyin, Norway, June, 1986.
7. Considerations in Drug Therapy for Older Adults, lecture and discussion for patient and

- family group at Frostburg Village Nursing Home, Frostburg, Maryland, July, 1987.
8. Effect of Data Collection Method on Results of Serum Digoxin Concentration Audit, Annual Preceptor Symposium Conference, School of Pharmacy, University of Maryland, Baltimore, Maryland, May, 1988.
  9. Perspectives on Psychotropic Drug Usage Evaluation, presented as a seminar to faculty at West Virginia University, Morgantown, West Virginia, September, 1988.
  10. Psychoactive Drugs and Older Adults, presented in a continuing education program "Medication Management for Older Adults" for health care professionals, Cumberland, Maryland, April, 1989, and September, 1989.
  11. Pharmacy: A Profession in Transition, presented as a seminar and discussion to the staff of the University Affiliated Center for the Developmentally Disabled, West Virginia University, Morgantown, WV, November, 1989.
  12. Psychotropic Drug Use in the Elderly," presented in a continuing education program "Drugs and the Elderly," Wheeling, West Virginia, November, 1989.
  13. Rational Use of the Antipsychotics, Weston State Psychiatric Hospital, Weston, West Virginia, February, 1990.
  14. Anxiety Disorders and Primary Care: A New Approach to Diagnosis and Management, continuing education for pharmacists, Fayette County Pharmaceutical Association, Uniontown, Pennsylvania, November, 1990; Three Rivers College of Clinical Pharmacy, Morgantown, WV, October, 1990; Allegheny Pharmaceutical Association, Rochester, PA, September, 1990; Valley Pharmaceutical Association, Martinsburg, WV, September, 1990.
  15. Patient Counseling and Drug Product Selection, presented in a continuing education program "Drug Product Selection: Making a Professional Choice, Southern Appalachian Pharmacy Association, Athens, WV, October, 1990.
  16. Psychotropic Drugs and the Elderly, presented in a continuing education program "Drugs and the Elderly," for the Gerontology Center, Parkersburg, WV, December, 1990.
  17. Update on Anxiety Disorders: Concerns for the Pharmacist, presented as a continuing education program for the Ohio-Marshall County Pharmacist Association, Wheeling, WV, February, 1991; Armstrong-Westmoreland County Pharmaceutical Association, Delmar, PA, January, 1991; Harrison County Pharmaceutical Association, Bridgeport, WV, December, 1990.
  18. Rational Use of the Antipsychotics, Monongalia Valley Pharmacist Association, Morgantown, WV, March, 1991.
  19. Prescription Drug Addiction, presented as a workshop in the conference "Issues In Treating Women's Addictions," sponsored by the Appalachian Mental Health Center and the West Virginia Department of Health and Human Services, Charleston, WV, March, 1991.
  20. Obsessive-Compulsive Disorder: The Illness and Its Management, Monongalia Valley Pharmacist Association, Fairmont, WV, April, 1991.
  21. Treatment of Hypertension in Older Adults: Focus on the ACE Inhibitors, Ashland Pharmacy Association, Ashland, KY, November, 1991; Southern West Virginia Pharmacists Association, Huntington, WV, November, 1991.
  22. Those Nagging Anxiety Disorders: Concerns for the Pharmacists, presented as a continuing education program at a regional meeting for Super-X pharmacists, Beckley, WV, January, 1992.
  23. Psychotropic Drugs in Older Adults, presented in a continuing education program "Drugs and the Elderly," for the Gerontology Center, Cumberland, MD, February, 1992.

24. Perspectives on Parkinsonism,” Monongalia Valley Pharmacist Association, Fairmont, WV, March, 1992.
25. Depression: Current Concepts and Treatment, 32nd Annual Spring Alumni Seminar, School of Pharmacy, West Virginia University, Morgantown, WV, April, 1992.
26. Appropriate Use/Adverse Effects of Psychotropic Drugs, presented for the West Virginia Eastern Region National Association of Social Workers, Martinsburg, WV, September, 1992.
27. Depression: Current Concepts and Treatment, presented for the Southern Appalachian Pharmacy Association, Athens, WV, September, 1992; Barbour, Randolph, Upshur, and Tucker Counties Pharmacy Association, Elkins, WV, September, 1992.
28. Extrapyramidal Side Effects of the Antipsychotics, presented at “Senior Care 1992,” West Virginia University, Morgantown, WV, October, 1992.
29. A Review of Disorders Leading to Psychosis and Indications for Antipsychotic Drug Use, presented at Senior Care 1992, West Virginia University, Morgantown, WV, October, 1992.
30. Managing Motor Response Fluctuations in Parkinson’s Disease: Therapeutic Agents and Pharmacokinetics, presented in a program “Managing for Practical Patient Outcomes in Parkinson’s Disease” for consultant pharmacists, Lexington, KY, November, 1992.
31. Depression: Current Concepts and Treatment, presented for the Monongalia County Hospital Pharmacists Association, Morgantown, WV, January, 1993.
32. Appropriate Use/Adverse Effects of Psychotropic Drugs, presented for the Valley Mental Health Mobile Mental Health Crisis Intervention Team, Morgantown, WV, February, 1993.
33. Chemical Abuse in the Pharmacy Profession: What to Do??. presented as invited speaker for Annual Hygeia Day Banquet, Lambda Kappa Sigma pharmacy service fraternity, Morgantown, WV, April, 1993.
34. Psychosis, Schizophrenia, and Treatment, presented as invited lecturer to Doctor of Pharmacy degree candidates, State University of New York, Buffalo, New York, April, 1993.
35. Overview of Psychotropic Medications, Agency for Retarded Citizens (ARC), Clarksburg, WV, February, 1994.
36. Cahill J, Makela EH. Pharmacotherapy and Schizophrenia, Seventh Annual Statewide Conference and Annual Meeting, West Virginia Alliance for the Mentally Ill, Morgantown, WV, March, 1994.
37. Adverse Effects of Antipsychotic Medications, William Sharpe Psychiatric Hospital, Weston, WV, April, 1994.
38. Assessing the Patient for Extrapyramidal Symptoms, William Sharpe Hospital, Weston, WV, June, 1994.
39. Makela EH. Role of Risperidone Versus Older Agents for Schizophrenia, invited speaker, Virginia Society of Hospital Pharmacists, Norfolk, VA, September, 1994.
40. Rational Use of Psychotropic Medications,” Heartland of Preston County nursing home, Kingwood, WV, August, 1994.
41. Reflections of a Clinical Pharmacist,” presented during Appalachian Family Center Workshop “Psychotropic Medications: A Workshop for the Non-Medical Professional,” Morgantown, WV, October, 1994.
42. Appropriate Use and Adverse Effects of Psychotropic Medications , The Arbors nursing home, Fairmont, WV, March, 1995.
43. Rational Treatment of Depression with Antidepressants, Grand Rounds, Department of

- Obstetrics and Gynecology, School of Medicine, West Virginia University, Morgantown, WV, May, 1995.
44. Monitoring for Extrapramidal Symptoms: Medico-legal Aspects, Grand Rounds, Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, November, 1995.
  45. Drug and Alcohol Interactions, Television interview for Dr. Bob Health Report , WBOY-TV, Clarksburg, WV, January, 1996.
  46. Psychopharmacology Update, Allegany Community College, Cumberland, MD, April, 1996.
  47. Makela EH. Depression: An Opportunity for Pharmaceutical Care? invited speaker, West Virginia Pharmacists Association 89th Annual Convention, Wheeling, WV, August, 1996.
  48. Makela EH, Vanin J. Obsessive-Compulsive Disorder, WWVU-FM Radio "Feedback" program, Morgantown, West Virginia, September, 1996.
  49. Adverse Effects of Antipsychotics: New and Old, Conference on Current Issues in Psychiatry: Addiction and Schizophrenia, Hot Springs, VA, June, 1997.
  50. St. Johns' Wort, Television interview for Dr. Bob Health Report , Wheeling, Clarksburg, and Huntington, WV, August, 1997.
  51. Makela EH, Lingle JS. Drug Development and Clinical Use of Atypical Antipsychotics, Schizophrenia: Here and Now, West Virginia University Annual Thought Disorders Conference Psychosis '97, William Sharpe Jr. Psychiatric Hospital, Weston, WV, September, 1997.
  52. CNS Drugs, Mental Health Seminar, Blackwater Falls Lodge, Davis, West Virginia, October, 1997.
  53. Update on the Pharmacological Treatment of Schizophrenia, Thought Disorders Program, Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, WV, December, 1997.
  54. New Meds for Older Folks, Heartland of Preston County nursing home, Kingwood, WV, February, 1998.
  55. Makela EH, Cutlip WC. "Schizophrenia," Weekly viewer call-in television program *Doctors on Call* , West Virginia Public Television WNPB-TV, West Virginia Public Television WNPB-TV, February, 1998.
  56. Treatment of Neurobehavioral Aspects of Dementia, Heartland of Preston County nursing home, Kingwood, W Treatment of Neurobehavioral Aspects of Dementia," Doctors Appreciation Day, Heartland of Preston County nursing home, Kingwood, West Virginia, March, 1998., March, 1998.
  57. Assessment of Side Effects of Antipsychotics, West Virginia University Annual Thought Disorders Conference: Psychosis '98, Morgantown, W Assessment of Side Effects of Antipsychotics," West Virginia University Annual Thought Disorders Conference: Psychosis 98, Morgantown, West Virginia, September, 1998., September, 1998.
  58. Adverse Effects of the Antipsychotics: Old and New, Noon Conference, Department of Family Practice Medicine, West Virginia University, Morgantown, WV, July, 1999.
  59. Chemical Abuse and Drug-Seeking Behavior, School of Dentistry Alumni Conference, West Virginia University, Morgantown, WV, April, 2000.
  60. Makela EH. Pharmacist's Role in Recognizing and Treating Depression, invited speaker, West Virginia Pharmacists Association 93<sup>rd</sup> Annual Convention, White Sulphur Springs, WV, June, 2000.

61. Obsessive-Compulsive Disorder and Psychosis, West Virginia University Annual Thought Disorders Conference: Psychosis 2000, Morgantown, West Virginia, September, 2000.
62. Diagnostic and Clinical Rating Scales, Psychiatry Grand Rounds, West Virginia University Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, November, 2000.
63. Obsessive-Compulsive Disorder in the Thought Disorders Clinic, Psychiatry Grand Rounds, West Virginia University Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, December, 2000.
64. Treatment of Psychosis. Northwestern Pennsylvania Society of Health-System Pharmacists, Erie, PA, April, 2002.
65. Moeller KE, Makela EH. Drugs and the Elderly, Morgantown Kiwanis, Morgantown, WV, April, 2002.
66. Research, The University Perspective. Neurosciences Research Retreat, West Virginia University Department of Behavioral Medicine and Psychiatry, Canaan Valley, WV, August, 2002.
67. Makela EH, Pope J. New Medications for the treatment of Mental Illness. Morgantown National Alliance for the Mentally Ill, Morgantown, WV, September, 2002.
68. Advances in the Treatment of Psychosis: Focus on the Atypical Antipsychotics. Warren State Psychiatric Hospital, Warren, PA, April, 2003.
69. Makela EH, Brister C, Fullen JE. Substance Abuse in the Pharmacy Profession. Continuing education program for area pharmacists. Morgantown, WV, March, 2004.
70. Makela EH, Latocha M. Current Topics and Issues in Psychiatry. Morgantown National Alliance for the Mentally Ill, Morgantown, WV, April, 2004.
71. Duckworth K, Makela EH, Getting the Most Out of Your Psychiatric Medications, Twenty-fifth Annual Convention of the National Alliance for the Mentally Ill, Washington, D.C., September, 2004.
72. Makela EH, Research Presentations, Branded versus generic clozapine for treatment of schizophrenia, speaker and moderator, West Virginia University 8th Annual Thought Disorders Conference: Psychosis 2004, Morgantown, WV, September, 2004.
73. Makela EH, Fidler D. "Mental Health and Medications" Weekly viewer call-in television program *Doctors on Call*, West Virginia Public Television WNPB-TV, scheduled October 14, 2004.
74. Makela EH. Depression and its treatment: ruminations of a psychiatric pharmacist. Invited keynote speaker, Lambda Kappa Sigma Annual Hygeia Dinner, Morgantown, West Virginia, April, 2005.
75. Makela EH, Caley C. Curbside Chat Booth discussant, co-sponsored by the National Alliance for the Mentally Ill and the College of Psychiatric and Neurologic Pharmacists, Annual Convention of the National Alliance for the Mentally Ill, Austin, Texas, June, 2005.
76. Makela EH, Dufresne R. Medication Therapy Update: Antipsychotics, Antidepressants, and Mood Stabilizers, speaker and moderator, Annual Convention of the National Alliance for the Mentally Ill, Austin, Texas, June, 2005.
77. Makela EH, Hawley J, others. Curbside Chat Booth discussant, co-sponsored by the National Alliance for the Mentally Ill and the College of Psychiatric and Neurologic Pharmacists, Annual Convention of the National Alliance for the Mentally Ill, Washington, D.C., June, 2006.
78. Obsessive Compulsive Disorder, Television interview for Dr. Bob Health Report, WBOY-

- TV, Clarksburg, WV, January, 2007.
79. Sommi RW, Dufresne RL, Lacro JP, Makela EH, Dugan D. "Effectiveness as a Driver of Change: Impact of Antipsychotic Trials on Policy and Practice," symposium presented at 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, Colorado, April, 2007.

### **ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT MEETINGS**

1. Caldwell D, Makela EH, Pigg P. "Survey of Clinical Pharmacy Services in South Carolina," 20th Annual American Society of Hospital Pharmacists (ASHP) Midyear Clinical Meeting, New Orleans, Louisiana, December, 1985. (poster, published meeting abstract)
2. Makela EH. "Appropriate Use of Serum Digoxin Concentrations," presentation of preliminary results at the Seventeenth Annual Southeastern Conference for Post-Graduate Pharmacy Education and Training, University of Georgia, Athens, GA, March, 1986.
3. Makela EH, Watkins R. Provision of Group Medication Education to Psychiatric Inpatients Utilizing Undergraduate Pharmacy Students. Ninth Annual National Council on Patient Information and Education (NCPIE), Washington, DC, May, 1993 (poster); 23rd Annual Meeting of the American Society of Consultant Pharmacists, Orlando, FL, November, 1992. (poster, published meeting abstract)
4. Makela EH. Differentiation of Dementia, Delirium, and Depression in the Geriatric Patient, presented for the Psychopharmacy Specialty Practice Group, ASHP 27th Annual Midyear Clinical Meeting, Orlando, FL, December, 1992.
5. Warren DA, Haut MW, Cahill JF, Cutlip WD, Stevenson JM, Makela EH. Working memory capacity in schizophrenia, *Clinical Neuropsychologist* 1993;7(3):352. (abstract)
6. Makela EH. Pharmacotherapy of Schizophrenia: Old and New Agents, invited speaker at the Spring Conference of the West Virginia Psychological Association, Charleston, WV, April, 1994.
7. Makela EH, Vanin J, Swain EL, Hobbs G, Linger B. Obsessive-Compulsive Symptoms and Standardized Reading Test Scores. 34th Annual Meeting of the New Clinical Drug Evaluation Unit, Division of Clinical and Treatment Research, National Institute of Mental Health, Marco Island, Florida, June, 1994. (poster, abstract citation: *Psychopharmacology Bulletin* 1994;30(4):692); School of Medicine Research Day, West Virginia University, Morgantown, WV, April, 1995. (poster, published meeting abstract); Winter Practice and Research Forum, American College of Clinical Pharmacy, Monterey, CA, February, 1996. (poster, published meeting abstract)
8. Makela EH, Madhavan S, Pinto L. Assessment of Practice Standards: Informed Consent for Antipsychotic Drug Usage and Monitoring for Extrapiramidal Effects. 36th Annual Meeting of the New Clinical Drug Evaluation Unit, Division of Clinical and Treatment Research, National Institute of Mental Health, Boca Raton, FL, May, 1996. (poster, abstract citation: *Psychopharmacology Bulletin* 1996); International Congress on Schizophrenia Research, Colorado Springs, Colorado, April, 1997. (poster)
9. Robyn S, Haut MW, Stevenson JM, Makela EH. Working memory function in schizophrenia, *Journal of the International Neuropsychological Society* 1996;2(1):23. (abstract)
10. Makela EH, Stamatakis MK, Hill LA. Scientific / Scholarly Writing for Publication: A Course for B.S. in Pharmacy Candidates. Annual Meeting of the American Association of

- Colleges of Pharmacy, Indiannapolis, Indiana, July, 1997. (poster, published meeting abstract)
11. Makela EH, Cutlip WD, Abdallah E, et al. A Non-Blinded Switch from Branded to Generic Clozapine: Effects on Clinical Status. West Virginia University School of Medicine Research Day, Morgantown, WV, April, 2000. (poster, published meeting abstract); 42nd Annual Meeting of the New Clinical Drug Evaluation Unit Conference Proceedings, Division of Clinical and Treatment Research, National Institute of Mental Health, Boca Raton, Florida, June, 2002. (poster, published meeting abstract); College of Psychiatric and Neurologic Pharmacists (CPNP) 6th International Meeting Conference Proceedings, Charleston, South Carolina, May, 2003. (poster, published meeting abstract)
  12. Schumacher J, Griffin H, Makela EH, McCoy G. Assessment of Multiple Antipsychotic Use in a University-Affiliated State Psychiatric Hospital. ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December, 2000 (resident poster, research in progress); International Meeting of the College of Psychiatric and Neurologic Pharmacists, San Antonio, TX, March, 2001. (resident poster, research in progress, published meeting abstract);
  13. Schumacher J, Griffin H, Makela EH, McCoy G. Assessment of Multiple Antipsychotic Use in a University-Affiliated State Psychiatric Hospital. West Virginia University School of Medicine Research Day, Morgantown, WV, April, 2001. (poster, published meeting abstract); Twentieth Annual Eastern States Conference for Pharmacy Residents and Preceptors Conference Proceedings. Baltimore, MD, April, 2001. (abstract)
  14. Moeller K, Makela EH, Schumacher J. Medication Control Issues in Borderline Personality Disorder. ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December, 2001. (resident poster-research in progress); West Virginia University School of Medicine Research Day Conference Proceedings, Morgantown, WV, April, 2002. (poster, published meeting abstract); 5th International Meeting of the College of Psychiatric and Neurologic Pharmacists, Seattle, WA, April, 2002. (poster, published meeting abstract)
  15. Tien A, Aboraya A, Abdullah E, Weimer J, Barnhart J, Makela EH. Computer indexing of psychiatric assessment, West Virginia University School of Medicine Research Day Conference Proceedings, Morgantown, WV, April, 2002. (poster, published meeting abstract)
  16. Pope J, Makela EH, Fullen J. Adherence to metabolic monitoring guidelines for atypical antipsychotics in a university-affiliated state psychiatric hospital. American Society of Health-System Pharmacists 38th Annual Midyear Clinical Meeting, Atlanta, Georgia, December, 2002. (resident poster, research in progress); West Virginia University School of Medicine Research Day Conference Day Proceedings, Morgantown, West Virginia, April, 2003. (poster, published abstract); 6th International Meeting of the College of Psychiatric and Neurologic Pharmacists, Charleston, SC, May, 2003. (poster, published meeting abstract)
  17. Kalsekar ID, Makela EH, Moeller KE. Assessment of utilization of drugs and prevalence of conditions leading to QT lengthening in patients with schizophrenia. Annual Meeting of the American Pharmaceutical Association, New Orleans, Louisiana, March, 2003. (poster, published meeting abstract); West Virginia University School of Medicine Research Day, Morgantown, WV, April, 2003. (poster, published meeting abstract)
  18. Coffindaffer JW, Miller K, Kavookjian J, Makela EH. Pharmacists' utilization and perceptions of drug interaction program warnings. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting, Crystal City, VA, May,

2003. (poster, published meeting abstract)
19. Thayer LA, Scott V, Nau D, Rosenbluth S, Makela EH. Evaluating the cost-effectiveness of St. John's Wort versus fluoxetine for the treatment of mild to moderate depression. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting, Crystal City, VA, May, 2003. (poster, published meeting abstract)
  20. Barnhart J, Makela EH. Serotonin specific reuptake inhibitor-induced apathy syndrome. West Virginia University School of Medicine Research Day, Morgantown, WV, April, 2003. (poster, published meeting abstract)
  21. Clemons WE, Makela EH, Young J. Concomitant Use of modafinil and tranlycypromine in a patient with narcolepsy. (poster) West Virginia University School of Medicine Research Day, Morgantown, WV, April, 2003.
  22. Makela EH. The Treatment of Psychosis: New Drugs... New Adverse Effects. Invited speaker, Joint Meeting of the West Virginia Pharmacists Association and the West Virginia Society of Health-System Pharmacists Annual Meeting, Charleston WV, April, 2003.
  23. Howsare J, Makela EH, Davis III W, Hough K. Managing your illness effectively: outpatient group therapy for patients diagnosed with schizophrenia and other thought disorders. West Virginia University School of Medicine Research Day Conference Proceedings, Morgantown, West Virginia, April, 2004. (poster, published meeting abstract)
  24. Latocha M, Makela EH, Kavookjian J, Biondo L, Fullen JE, Clausell P. Antidepressant-induced apathy. West Virginia University School of Medicine Research Day Conference Proceedings, Morgantown, WV, April, 2004. (poster, published meeting abstract); Antidepressant-induced apathy. College of Psychiatric and Neurologic Pharmacists 7th International Meeting Conference Proceedings, Chicago, Illinois, April, 2004. (poster, published meeting abstract)
  25. Giblin L, Makela EH, Latocha M. Prescribing patterns of atypical antipsychotics in patients discharged from a university-based psychiatric hospital. American Society of Health-System Pharmacists 40th Annual Midyear Clinical Meeting, Atlanta, Georgia, December, 2004. (resident poster, research in progress); 8th International Meeting of the College of Psychiatric and Neurologic Pharmacists, San Diego, California, March, 2005. (poster, published meeting abstract); West Virginia University Health Sciences Center Research Day Conference Day Proceedings, Morgantown, West Virginia, April, 2005. (poster, published abstract)
  26. Kalsekar I, Madhavan SM, Amonkar M, Douglas S, Makela EH, Scott V. Depression in patients with type-2 diabetes: impact on utilization patterns and adherence to oral hypoglycemic agents. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual International Meeting, Washington, D.C., May, 2005. (poster [best poster award], published meeting abstract)
  27. Kalsekar I, Madhavan SM, Amonkar M, Makela EH, Scott V, Douglas S. Impact of depression on incidence of type-2 diabetes in a state medicated population. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual International Meeting, Washington, D.C., VA, May, 2005. (poster, published meeting abstract)
  28. Kalsekar I, Madhavan S, Amonkar A, Douglas S, Makela E, Scott V. Depression in patients with type 2 diabetes: impact on initiation of insulin therapy. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual International Meeting, Washington, D.C., VA, May, 2005. (poster, published meeting abstract)
  29. Baird-Miller KE, Sager RB, Makela EH, Palmer CH. Haloperidol lactate use in a university

- teaching hospital. American Society of Health-System Pharmacists 41st Annual Midyear Clinical Meeting Conference Proceedings, Las Vegas, Nevada, December, 2005. (poster, published meeting abstract)
30. Baird-Miller KE, Makela EH. Assessment of Reading Skills in Children and Adolescents Diagnosed with Obsessive-Compulsive Disorder. West Virginia University Health Sciences Center Research Day Conference Day Proceedings, Morgantown, West Virginia, April, 2006. (poster, published abstract)
  31. Hassan M, Madhavan SS, Rajagopalan K, Kalsekar ID, Islam S, Makela EH, Kavookjian J, Miller LA. Comparing adherence and persistence with antipsychotic therapy among patients with bipolar disorder. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual International Meeting, Philadelphia, Pennsylvania, May, 2006. (poster, published abstract)
  32. Hassan M, Madhavan SS, Rajagopalan K, Kalsekar ID, Islam S, Makela EH, Kavookjian J, Miller LA. Antipsychotic therapy in patients with bipolar disorder: effects on total and mental health care costs. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual International Meeting, Philadelphia, Pennsylvania, May, 2006. (poster, published abstract)
  33. Hassan M, Madhavan S, Rajagopalan K, Islam S, Makela E, Kavookjian J, Miller L. Patterns of antipsychotic utilization among patients with schizophrenia in a state Medicaid program. American Psychiatric Association Annual Meeting, Toronto, Canada, May, 2006 (poster, published abstract)
  34. Hassan M, Madhavan S, Rajagopalan K, Islam S, Makela E, Kavookjian J, Miller L. Impact of antipsychotic use on mental health-related hospitalizations among patients with schizophrenia in a state Medicaid program. American Psychiatric Association Annual Meeting, Toronto, Canada, May, 2006 (poster, published abstract)

## **PUBLICATIONS**

### **REVIEW ARTICLES, LETTERS, BOOK REVIEWS, REPORTS**

1. Makela EH, Cutlip WD. Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet SR). *Journal of Neuropsychiatry and Clinical Neurosciences* 1992; 4(2),Spring: 234-35.
2. Makela EH, Watkins R. Utilizing undergraduate pharmacy students to develop and institute a hospital pharmacy service. *American Journal of Pharmaceutical Education* 1992;56(Fall):267-271.
3. Rakel R, Makela EH. Anxiety Profiles: New Perspectives for Diagnosis and Treatment, a monograph prepared for pharmacist's continuing education, Bristol-Myers Squibb Company, Princeton, NJ; 1992.
4. Makela EH. Everybody councils...right! *American Pharmacy* 1993;NS33(8):5 (letter).
5. Makela EH. Atypicality of clozapine. *Annals of Pharmacotherapy* 1993;27:1540-41 (letter).

6. Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? *Annals of Pharmacotherapy* 1994;28:67-71.
7. Makela EH. The One Minute Counselor: A pharmacist's guide to chronic fatigue syndrome; A patient's guide to chronic fatigue syndrome. *American Pharmacy* 1994;NS34(No.4); *The ACCP Report*:7-8.
8. Makela EH. Understanding chronic fatigue syndrome. *American Pharmacy* 1994; NS34(No.4): 45-56.
9. Makela EH, Sullivan P, Taylor M. Sertraline and speech blockage. *Journal of Clinical Psychopharmacology* 1994;14(6):432-33.
10. Makela EH. Basic Bibliographies: Chronic fatigue syndrome. *Hospital Pharmacy* 1995;30(10): 941-2.
11. Makela EH, Sullivan P. Reply to letter by Christensen, Byerly, and McElroy "A case of sertraline-induced stuttering," *Journal of Clinical Psychopharmacology* 1996;16(1):93.
12. Eddy JT, Stamatakis MK, Makela EH. *Saccharomyces boulardii* for the treatment of *Clostridium difficile* -associated colitis. *Annals of Pharmacotherapy* 1997;31:919-21.
13. Makela EH. "Symptom-Focused Psychiatric Drug Therapy for Managed Care," *American Journal of Pharmaceutical Education* 1998 (spring);62:107. (book review)
14. Makela EH. Understanding Obsessive Compulsive Disorder. *Pharmacy Times* 1998 (October):100-110.
15. Rack SK, Makela EH. Hypothyroidism and depression: a therapeutic challenge. *Annals of Pharmacotherapy* 2000;34:1142-5.
16. Makela EH. Essential Psychopharmacology of Antipsychotic Drugs and Mood Stabilizers. *American Journal of Pharmaceutical Education* 2002 (winter);66:471-2. (book review)
17. Makela EH, Miller K, Cutlip WD. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. *Journal of Clinical Psychiatry* 2003;64:485-86. (letter)
18. Pope JE, Makela EH. Response to article "Depression circumstantially related to the administration of finasteride for androgenic alopecia." *The Journal of Dermatology* 2003;30:837-839.
19. Makela EH, Griffith RK. Enhancing treatment of bipolar disorder using patient's belief system. *Annals of Pharmacotherapy* 2003;37:543-45.

20. Barnhart W, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. *Journal of Psychiatric Practice* 2004;10:196-199.
21. Clemons WE, Makela EH, Young J. Concomitant use of modafinil in a patient with narcolpsy : a case report. *Sleep Medicine* 2004;5:509-11.
22. Makela EH. Pharmacy Students "Act Out" in CE Program. West Virginia University School of Pharmacy alumni publication *The ShowGlobe*, 2005.
23. Aboraya A, Fullen JE, Ponieman BL, Makela EH, Latocha M. Hyperprolactinemia associated with risperidone. A case report and review of the literature. *Psychiatry* 2004 (November):29-31.
24. Moreland A, Makela EH. Selective Serotonin Reuptake Inhibitors in the Treatment of Premature Ejaculation. *Annals of Pharmacotherapy* 2005;39:1296-301.

### **DRUG INFORMATION BULLETINS**

1. Makela EH. Medications Used for Aggression or Violence. *Drug Information Bulletin*, Vol.14, No.10, Drug Information Center publication, West Virginia University, July/August, 1989.
2. Makela EH. Recently Released Drugs: Clomipramine. *Drug Information Bulletin*, Vol. 15, No. 8, Drug Information Center publication, West Virginia University, May, 1990.
3. Makela EH. Adverse Effects of the Antipsychotics: Extrapyramidal Side Effects. *Drug Information Bulletin*, Vol. 16, No. 6, Drug Information Center publication, West Virginia University, March, 1991.
4. Makela EH. Drugs in the FDA 'Pipeline': Sertraline. *Drug Information Bulletin*, Vol. 17, No. 1, Drug Information Center publication, West Virginia University, October, 1991.
5. Makela EH. Clozapine (Clozaril): the "atypical" drug. *Drug Information Bulletin*, Vol. 17, No. 9, Drug Information Center publication, West Virginia University, June, 1992.

### **RESEARCH REPORTS**

1. Makela EH, Davis SK, Piveral K, Miller WA, Pleasants RA, Gadsden RH, Leman RB. Effect of data collection method on results of serum digoxin concentration audit. *Am Journal of Hospital Pharmacy*. 1988; 45: 126-30.
2. Makela EH, Brister C, Kahle K, Madhavan S. Impaired Pharmacists Committee [results of a statewide survey]. *Mountain State Pharmacist* 1993;September:2.
3. Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM. On the nature

- of wisconsin card sorting test performance in schizophrenia. *Psychiatry Research* 1996;65:15-22.
4. Makela EH, Cutlip WD, Stevenson JM, Weimer JM, Abdallah ES, Akhtar RS, Aboraya AS, Gunel E. Branded versus generic clozapine for treatment of schizophrenia. *Annals of Pharmacotherapy* 2003;37:350-53.
  5. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. *Annals of Pharmacotherapy* 2003;37:951-5.
  6. Kalsekar ID, Makela EH, Moeller KE. Analysis of West Virginia Medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia. *Current Therapeutic Research* 2003;64:538-550.
  7. Nuss MA, Elnicki DM, Dunsworth TS, Makela EH. Utilizing the CIWA-Ar to assess use of benzodiazepines in patients vulnerable to alcohol withdrawal syndrome. *West Virginia Medical Journal* 2004;99:21-25.
  8. Kalsejar ID, Madhavan S, Amonkar M, Makela EH, Scott V, Douglas S, Elswick B. Depression in patients with type 2 diabetes: Impact on adherence to oral hypoglycemic agents. *Annals of Pharmacotherapy* 2006;40:605-611.
  9. Makela EH, Moeller KE, Fullen JE, Gunel E. Medication utilization patterns and methods of suicidality in borderline personality disorder. *Annals of Pharmacotherapy* 2006;40:49-52.
  10. Kalsejar ID, Madhavan S, Amonkar M, Douglas S, Makela EH, Elswick B, Scott V. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes: A retrospective cohort analysis. *Clinical Therapeutics* 2006;28(2):306-318.
  11. Kalsejar ID, Madhavan S, Amonkar M, Scott V, Douglas S, Makela EH. Impact of depression on healthcare utilization and costs in patients with type 2 diabetes: A retrospective database analysis. *Managed Care Interface* 2006;40:39-46.
  12. Hassan M, Makela EH et al. Comparing adherence and persistence with antipsychotic therapy among patients with bipolar disorder. *Psychiatric Services* (in press).

## **BOOK CHAPTERS**

Kirkwood C, Makela EH, Wells B. Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder. In: DiPiro, Wells eds., *Pharmacotherapy* 6th ed., 2005:1307-1320.

## **GRANTS AND AWARDS**

1. Makela EH. (Principal Consultant)., Technical Assistance and Consultation for the Department of Pharmacy, Weston State Hospital, Weston, West Virginia, University

- Affiliated Center for the Developmentally Disabled (UACDD); 1990-91: \$4,200
2. Makela EH, Brister C, Kahle K. Survey of West Virginia Pharmacists on Impaired Practitioner Program, Anonymous Donor; 1992: \$500
  3. Makela EH. Support to attend and present at the ASHP Midyear Clinical Meeting, December, 1992: \$340
  4. Makela EH, Rosenbluth SA (Principal Consultant). Technical Assistance and Consultation for the Department of Pharmacy, Wm. Sharpe, Jr. Hospital, Weston, West Virginia, University Affiliated Center for the Developmentally Disabled (UACDD); 1993-94: \$7,470
  5. Makela EH, Madhavan S. (Principal Investigator). Assessment of Practice Standards: Informed Consent for Antipsychotic Drug Usage and Monitoring for Extrapyramidal Side effects, West Virginia University Senate Grant; 1993-94: \$5,000
  6. Makela EH, Clausell P (Co-Principal Investigators), Aboraya A, Adamski T, Young J. A Double-Blind, Placebo-Controlled, Dose-Response Comparison of the Safety and Efficacy of Three Doses of Sertindole and Three Doses of Haldol® in Schizophrenic Patients, Abbott Laboratories; 1994-95: \$252,075
  7. Makela EH, Clausell P (Co-Principal Investigators), Aboraya A, Adamski T, Young J. An Open-Label Assessment of the Long-Term Safety of Sertindole in the Treatment of Schizophrenic Patients, Abbott Laboratories; 1994-95: \$32,270
  8. Makela EH, Clausell P (Co-Principal Investigators), Aboraya A, Young J, Rozzell M. Safety and Efficacy of Risperidone 8mg Every Day and 4mg Every Day Compared to Placebo in the Treatment of Schizophrenia, Janssen Pharmaceutica; 1995-96: \$53,500
  9. Makela EH, Clausell P (Co-Principal Investigators), Aboraya A, Young J. An Open-Label Assessment of the Long-Term Safety of Sertindole, Abbott Laboratories; 1995-98: \$32,890
  10. Makela EH, Vanin J (Principal Investigator). The Effect of Fluvoxamine on Reading Test Scores in Patients With Obsessive-Compulsive Disorder, Solvay Pharmaceuticals, 1995-99: \$27,600est. reflecting cost of medication provided by Solvay to support project.
  11. Nuss S, Hargro G, Makela EH, Elnicki DM, Dunsworth T. Appropriate and Cost Efficient Use of Benzodiazepines in the Alcohol Withdrawal Syndrome, West Virginia University Hospitals (Enhanced Patient Care Grant), 1999-2001: \$12,000
  12. Aboraya A, LePage J, France C, Makela EH. Computer Indexing of Psychiatric Assessment, Medical Decision Logic, Inc., 2000-2003: \$52,808
  13. Makela EH, Cutlip WD. Unrestricted Educational Grants from pharmaceutical industry (Eli Lilly, others) to support the 3th Annual Thought Disorders Conference: Psychosis 1999: \$9,751

14. Makela EH, Cutlip WD. Unrestricted Educational Grants from pharmaceutical industry (Eli Lilly, others) to support the 4th Annual Thought Disorders Conference: Psychosis 2000: \$12,340
15. Makela EH, Cutlip WD. Unrestricted Educational Grants from pharmaceutical industry (Bertek, Astra Zeneca, others) to support the 5th Annual Thought Disorders Conference: Psychosis 2001: \$16,392
16. Makela EH. Unrestricted Educational Grant to support education of Psychiatric Pharmacy resident. Eli Lilly, 2001: \$500.
17. Makela EH. Unrestricted Educational Grant to support education of Psychiatric Pharmacy resident. Eli Lilly, 2002: \$500.
18. Kalsekar I, Amonkar M, Makela EH. Assessment of utilization of drugs and prevalence of conditions leading to QT lengthening, Eli Lilly, 2002: \$5,000.
19. Makela EH, Cutlip WD. Unrestricted Educational Grants from pharmaceutical industry (Bertek, Janssen, Eli Lilly, Pfizer, Astra Zeneca) to support the 6th Annual Thought Disorders Conference: Psychosis 2002: \$15,000
20. Makela EH. Unrestricted Educational Grant to support education of Psychiatric Pharmacy resident. Eli Lilly, 2003: \$500.
21. Makela EH, Cutlip WD. Unrestricted Educational Grants from pharmaceutical industry (Bertek, Janssen, Eli Lilly, Pfizer, Astra Zeneca) to support the 7th Annual Thought Disorders Conference: Psychosis 2003: \$18,663
22. Makela EH, Young J. Unrestricted Educational Grants from pharmaceutical industry (Mylan/Bertek, Johnson and Johnson, Pfizer, Astra Zeneca) to support the 8th Annual Thought Disorders Conference: Psychosis 2004: \$8,500.
23. Makela EH, Young J. Unrestricted Educational Grants from pharmaceutical industry (Mylan, Eli Lilly, Astra Zeneca) to support the 9th Annual Thought Disorders Conference: Psychosis 2005: \$5,000.